A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon (IFN)-β 1a potently inhibits SARS coronavirus replication in vitro
Compounds approved for therapeutic use and in vitro inhibitors of severe acute respiratory syndrome ...
Interferon (IFN)-alpha, -beta and -gamma have been shown to be only marginally effective against sev...
Inhaled nebulized interferon (IFN)-α and IFN-β have been shown to be effective in the management of ...
A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in...
The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to tr...
The ongoing COVID-19 pandemic has forced the clinical and scientific community to try drug repurposi...
AbstractRecent studies have shown that interferon-gamma (IFN-γ) synergizes with IFN-α/β to inhibit t...
Type III interferons (lambda IFNs) are a quite new, small family of three closely related cytokines ...
INTRODUCTION: The pandemic spread of a new coronavirus infection, COVID-19, has caused a global emer...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 ...
Background: There is an urgent need for new antivirals with powerful therapeutic potential and toler...
Background: There is an urgent need for new antivirals with powerful therapeutic potential and toler...
Severe acute respiratory syndrome (SARS) is caused by the SARS coronavirus (SCV). The disease appear...
A previously unknown coronavirus (CoV) is the aetiological agent causing severe acute respiratory sy...
There is currently an urgent need to identify effective antiviral agents that will prevent and treat...
Compounds approved for therapeutic use and in vitro inhibitors of severe acute respiratory syndrome ...
Interferon (IFN)-alpha, -beta and -gamma have been shown to be only marginally effective against sev...
Inhaled nebulized interferon (IFN)-α and IFN-β have been shown to be effective in the management of ...
A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in...
The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to tr...
The ongoing COVID-19 pandemic has forced the clinical and scientific community to try drug repurposi...
AbstractRecent studies have shown that interferon-gamma (IFN-γ) synergizes with IFN-α/β to inhibit t...
Type III interferons (lambda IFNs) are a quite new, small family of three closely related cytokines ...
INTRODUCTION: The pandemic spread of a new coronavirus infection, COVID-19, has caused a global emer...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 ...
Background: There is an urgent need for new antivirals with powerful therapeutic potential and toler...
Background: There is an urgent need for new antivirals with powerful therapeutic potential and toler...
Severe acute respiratory syndrome (SARS) is caused by the SARS coronavirus (SCV). The disease appear...
A previously unknown coronavirus (CoV) is the aetiological agent causing severe acute respiratory sy...
There is currently an urgent need to identify effective antiviral agents that will prevent and treat...
Compounds approved for therapeutic use and in vitro inhibitors of severe acute respiratory syndrome ...
Interferon (IFN)-alpha, -beta and -gamma have been shown to be only marginally effective against sev...
Inhaled nebulized interferon (IFN)-α and IFN-β have been shown to be effective in the management of ...